Lmcg Investments LLC Has $5.02 Million Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Lmcg Investments LLC lowered its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 13.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 46,465 shares of the medical equipment provider's stock after selling 7,212 shares during the period. Lmcg Investments LLC's holdings in Zimmer Biomet were worth $5,016,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Biechele Royce Advisors boosted its stake in shares of Zimmer Biomet by 21.0% during the 3rd quarter. Biechele Royce Advisors now owns 66,110 shares of the medical equipment provider's stock valued at $7,137,000 after buying an additional 11,496 shares during the last quarter. Chicago Partners Investment Group LLC grew its holdings in Zimmer Biomet by 9.4% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 3,220 shares of the medical equipment provider's stock worth $337,000 after acquiring an additional 277 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of Zimmer Biomet by 11.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 5,825 shares of the medical equipment provider's stock worth $629,000 after purchasing an additional 587 shares during the last quarter. Lowe Brockenbrough & Co. Inc. raised its stake in shares of Zimmer Biomet by 2.9% in the 3rd quarter. Lowe Brockenbrough & Co. Inc. now owns 5,470 shares of the medical equipment provider's stock valued at $592,000 after purchasing an additional 156 shares in the last quarter. Finally, Creative Financial Designs Inc. ADV lifted its position in shares of Zimmer Biomet by 23.6% during the third quarter. Creative Financial Designs Inc. ADV now owns 771 shares of the medical equipment provider's stock worth $83,000 after purchasing an additional 147 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on ZBH shares. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research note on Thursday. JPMorgan Chase & Co. reduced their price objective on Zimmer Biomet from $125.00 to $120.00 and set a "neutral" rating on the stock in a research note on Monday, September 16th. Canaccord Genuity Group decreased their target price on Zimmer Biomet from $120.00 to $115.00 and set a "hold" rating for the company in a research note on Tuesday, September 10th. BTIG Research dropped their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating on the stock in a report on Thursday, October 3rd. Finally, Evercore ISI lowered their target price on Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating on the stock in a research report on Tuesday, October 1st. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of "Hold" and a consensus target price of $123.84.

Zimmer Biomet Trading Up 0.3 %

Shares of NYSE:ZBH traded up $0.35 during midday trading on Friday, reaching $107.27. The company had a trading volume of 1,905,699 shares, compared to its average volume of 1,409,299. The company has a fifty day simple moving average of $106.96 and a two-hundred day simple moving average of $110.81. The firm has a market cap of $21.35 billion, a price-to-earnings ratio of 20.39, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.63 and a current ratio of 1.36.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, missing the consensus estimate of $1.75 by ($0.01). Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the previous year, the business earned $1.65 earnings per share. The business's quarterly revenue was up 4.1% compared to the same quarter last year. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend was Monday, September 30th. Zimmer Biomet's dividend payout ratio (DPR) is currently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.